Sameer Doshi

1.3k total citations
48 papers, 1.0k citations indexed

About

Sameer Doshi is a scholar working on Oncology, Hematology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Sameer Doshi has authored 48 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 17 papers in Hematology and 10 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Sameer Doshi's work include Blood groups and transfusion (7 papers), Erythropoietin and Anemia Treatment (6 papers) and Monoclonal and Polyclonal Antibodies Research (6 papers). Sameer Doshi is often cited by papers focused on Blood groups and transfusion (7 papers), Erythropoietin and Anemia Treatment (6 papers) and Monoclonal and Polyclonal Antibodies Research (6 papers). Sameer Doshi collaborates with scholars based in United States, Belgium and Germany. Sameer Doshi's co-authors include Andrew Chow, Juan José Pérez Ruixo, Min Zhu, Jessica Johnson, Andreas Wolf, Christian Brandl, Graham Jang, Benjamin Wu, Mark Peterson and Liviawati Sutjandra and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and Journal of Neuroscience.

In The Last Decade

Sameer Doshi

48 papers receiving 998 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sameer Doshi United States	18	417	305	252	190	174	48	1.0k
Rosa Fonti Italy	23	560 1.3×	387 1.3×	489 1.9×	122 0.6×	354 2.0×	65	1.6k
Ivan de Kouchkovsky United States	8	228 0.5×	110 0.4×	582 2.3×	163 0.9×	561 3.2×	31	1.2k
Jianbo He United States	17	301 0.7×	118 0.4×	487 1.9×	113 0.6×	204 1.2×	49	1.1k
Jed Ross United States	15	454 1.1×	237 0.8×	690 2.7×	389 2.0×	25 0.1×	18	1.4k
Rachelle W. Johnson United States	26	1.0k 2.5×	145 0.5×	907 3.6×	225 1.2×	40 0.2×	55	1.8k
Derya Duranyıldız Türkiye	22	662 1.6×	77 0.3×	603 2.4×	282 1.5×	75 0.4×	85	1.4k
Arlene Berman United States	22	1.3k 3.1×	284 0.9×	614 2.4×	84 0.4×	99 0.6×	47	2.4k
Daisuke Tamura Japan	23	904 2.2×	202 0.7×	756 3.0×	100 0.5×	50 0.3×	67	1.9k
Giovanni Allevi Italy	17	603 1.4×	115 0.4×	437 1.7×	114 0.6×	24 0.1×	36	1.2k
Sergio Aguggini Italy	17	665 1.6×	121 0.4×	470 1.9×	116 0.6×	25 0.1×	34	1.3k

Countries citing papers authored by Sameer Doshi

Since Specialization

Citations

This map shows the geographic impact of Sameer Doshi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sameer Doshi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sameer Doshi more than expected).

Fields of papers citing papers by Sameer Doshi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sameer Doshi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sameer Doshi. The network helps show where Sameer Doshi may publish in the future.

Co-authorship network of co-authors of Sameer Doshi

This figure shows the co-authorship network connecting the top 25 collaborators of Sameer Doshi. A scholar is included among the top collaborators of Sameer Doshi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sameer Doshi. Sameer Doshi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lin, Chih‐Wei, et al.. (2023). A multistate platform model for time‐to‐event endpoints in oncology clinical trials. CPT Pharmacometrics & Systems Pharmacology. 13(1). 154–167. 2 indexed citations

Abuqayyas, Lubna, Po‐Wei Chen, Jane R. Parnes, et al.. (2023). Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Properties of Rozibafusp Alfa, a Bispecific Inhibitor of BAFF and ICOSL: Analyses of Phase I Clinical Trials. Clinical Pharmacology & Therapeutics. 114(2). 371–380. 12 indexed citations

Doshi, Sameer, Hui Wang, & Vincent Chow. (2022). Establishing PK Equivalence Between Adalimumab and ABP 501 in the Presence of Antidrug Antibodies Using Population PK Modeling. Clinical Therapeutics. 44(1). 111–122. 5 indexed citations

Clements, John D., et al.. (2019). Population Pharmacokinetics of Blinatumomab in Pediatric and Adult Patients with Hematological Malignancies. Clinical Pharmacokinetics. 59(4). 463–474. 13 indexed citations

Zhang, Yilong, et al.. (2016). Assessment of pharmacokinetic interaction between rilotumumab and epirubicin, cisplatin and capecitabine (ECX) in a Phase 3 study in gastric cancer. British Journal of Clinical Pharmacology. 83(5). 1048–1055. 5 indexed citations

Zhu, Min, Benjamin Wu, Christian Brandl, et al.. (2016). Blinatumomab, a Bispecific T-cell Engager (BiTE®) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications. Clinical Pharmacokinetics. 55(10). 1271–1288. 157 indexed citations

Doshi, Sameer, Per Olsson, Yilong Zhang, et al.. (2015). Rilotumumab Exposure–Response Relationship in Patients with Advanced or Metastatic Gastric Cancer. Clinical Cancer Research. 21(11). 2453–2461. 22 indexed citations

Koren, Michael J., Sameer Doshi, John P. Gibbs, et al.. (2015). Abstract 12729: Comparisons of Peak LDL-C Reduction and Duration of Effect With Lower or Higher Dosing Regimens of the PCSK9 Inhibitor Evolocumab. Circulation. 132(suppl_3). 1 indexed citations

Zhu, Min, Sameer Doshi, Per Olsson, et al.. (2013). Population Pharmacokinetics of Rilotumumab, a Fully Human Monoclonal Antibody Against Hepatocyte Growth Factor, in Cancer Patients. Journal of Pharmaceutical Sciences. 103(1). 328–336. 17 indexed citations

10.

Freeman, Daniel J., Kevin S. McDorman, Carl J. Kozlosky, et al.. (2012). Tumor penetration and epidermal growth factor receptor saturation by panitumumab correlate with antitumor activity in a preclinical model of human cancer. Molecular Cancer. 11(1). 47–47. 24 indexed citations

11.

Gibiansky, Leonid, Liviawati Sutjandra, Sameer Doshi, et al.. (2012). Population Pharmacokinetic Analysis of Denosumab in Patients with Bone Metastases from Solid Tumours. Clinical Pharmacokinetics. 51(4). 247–260. 69 indexed citations

12.

Sutjandra, Liviawati, Sameer Doshi, Mark Ma, et al.. (2011). Population Pharmacokinetic Meta-Analysis of Denosumab in Healthy Subjects and Postmenopausal Women with Osteopenia or Osteoporosis. Clinical Pharmacokinetics. 50(12). 793–807. 87 indexed citations

13.

Doshi, Sameer, et al.. (2011). Romiplostim Dose Response in Patients With Immune Thrombocytopenia. The Journal of Clinical Pharmacology. 52(10). 1540–1551. 9 indexed citations

14.

Boer, Richard de, Michael Clemens, Dusan Kotasek, et al.. (2010). Phase I/II randomised study of a novel erythropoiesis-stimulating agent (AMG 114) for the treatment of anaemia with concomitant chemotherapy in patients with non-myeloid malignancies. Medical Oncology. 28(4). 1210–1217. 2 indexed citations

15.

Wang, Yow‐Ming, Wojciech Krzyżański, Sameer Doshi, et al.. (2010). Pharmacodynamics-Mediated Drug Disposition (PDMDD) and Precursor Pool Lifespan Model for Single Dose of Romiplostim in Healthy Subjects. The AAPS Journal. 12(4). 729–740. 68 indexed citations

16.

Doshi, Sameer, Andrew Chow, & Juan José Pérez Ruixo. (2010). Exposure‐Response Modeling of Darbepoetin Alfa in Anemic Patients With Chronic Kidney Disease Not Receiving Dialysis. The Journal of Clinical Pharmacology. 50(S9). 75S–90S. 17 indexed citations

17.

Agoram, Balaji, Ken Aoki, Sameer Doshi, et al.. (2008). Investigation of the effects of altered receptor binding activity on the clearance of erythropoiesis-stimulating proteins: Nonerythropoietin receptor-mediated pathways may play a major role. Journal of Pharmaceutical Sciences. 98(6). 2198–2211. 26 indexed citations

18.

Elliott, Steven, Kenneth H. Aoki, Balaji Agoram, et al.. (2006). Evaluation of hyperglycosylated erythropoiesis stimulating proteins developed using glycoengineering. Cancer Research. 66. 514–514. 1 indexed citations

19.

Schmidt, Karl, Mateo Ziu, Nils Ole Schmidt, et al.. (2004). Volume Reconstruction Techniques Improve the Correlation Between Histological and in vivo Tumor Volume Measurements in Mouse Models of Human Gliomas. Journal of Neuro-Oncology. 68(3). 207–215. 77 indexed citations

20.

Sun, Yanping, Robert V. Mulkern, Karl Schmidt, et al.. (2004). Quantification of water diffusion and relaxation times of human U87 tumors in a mouse model. NMR in Biomedicine. 17(6). 399–404. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact